
Browsing restrictions can be lifted for a fee.
Sunmax Biotechnology Co., Ltd., a biomedical company, develops, manufactures, and markets collagen-based medical devices in Taiwan and Mainland China. The company offers Porcogen, a sterile purified collagen solution for medical device, tissue engineering, and research purposes; and dermal fillers, such as Sunmax collagen implant I-Plus, Sumax collagen implant I, Sunmax FACIALGAIN collagen implant with lidocaine, and Sunmax FACIALGAIN collagen implant 1-Plus with lidocaine for the correction of facial defects, such as the fill up of wrinkles. It also provides Sunmax collagen dental bone graft, Sunmax collagen dental membrane, and Sunmax dental bone graft granules, which are used in the augmentation or reconstructive treatment of the alveolar ridge, extraction sockets, and periodontology. In addition, the company offers Sunmax collagen bone graft matrix that provides a bone void filler that is resorbed and replaced with bone during the healing process; and skincare products comprising Sunmax 12 jiao didi spray, Sunmax 11 collagen moisturizing cream, and Sunmax collagen skincare that are used as aftercare of dermal filler treatment. Sunmax Biotechnology Co., Ltd. was founded in 2001 and is headquartered in Tainan City, Taiwan.
4728
雙美
-1.54%
(-0.02)
The most recent financial report for 雙美 (4728) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4728's short-term business performance and financial health. For the latest updates on 4728's earnings releases, visit this page regularly.
According to historical valuation range analysis, 雙美 (4728)'s current price-to-earnings (P/E) ratio is 22.88, placing it in the Overvalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
According to the latest financial report, 雙美 (4728) reported an Operating Profit of 258.56M with an Operating Margin of 51.34% this period, representing a growth of 10.93% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, 雙美 (4728) announced revenue of 503.6M, with a Year-Over-Year growth rate of 10.07%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
At the end of the period, 雙美 (4728) held Total Cash and Cash Equivalents of 536.09M, accounting for 0.28 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, 雙美 (4728) achieved the “three margins increasing” benchmark, with a gross margin of 77.89%%, operating margin of 51.34%%, and net margin of 37.66%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 4728's profit trajectory and future growth potential.
According to the past four quarterly reports, 雙美 (4728)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 3.48. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
雙美 (4728)'s Free Cash Flow (FCF) for the period is -14.91M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 5.67% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.